S 4447, the "Allowing Greater Access to Safe and Effective Contraception Act," would require the FDA to prioritize review of applications for oral contraceptives intended for routine use (excluding emergency contraception or abortion-related drugs), potentially enabling over-the-counter access for adults 18 and older. It includes a fee waiver for these applications and maintains prescription requirements for individuals under 18. The bill also mandates a GAO study on federal funding for contraception across programs like Medicaid, Medicare, and Title X over the past 15 years. These provisions aim to streamline approval for accessible birth control while clarifying funding patterns.
This bill requires the federal government to improve how states implement the Indian Child Welfare Act (ICWA) of 1978, directly affecting Indian tribes, state child welfare agencies, and tribal organizations. It mandates the Secretary of Health and Human Services to develop a plan by January 2025, using data to track specific ICWA compliance points like timely tribal notice in custody cases, active efforts to keep families together, and proper placement preferences for Indian children. The plan must include technical assistance for states and tribes, and the Secretary must submit biennial reports to Congress detailing state compliance and federal support efforts. These requirements aim to strengthen accountability and adherence to ICWA standards in child welfare proceedings.
HR 8639, the Warehouse Worker Protection Act, requires employers in covered warehouse facilities (including distribution centers, storage facilities, and delivery services) to provide workers with clear written descriptions of any quotas they're subject to, including how performance is measured and monitored. The bill prohibits quotas that interfere with breaks, safety compliance, or anti-discrimination protections, and mandates that employers provide employee work speed data in human-readable formats. It creates new anti-retaliation protections for workers who exercise these rights or file complaints, and establishes a Fairness and Transparency Office within the Department of Labor to oversee implementation. The act also amends the National Labor Relations Act to explicitly prohibit quotas that discourage workers from exercising their labor rights.
This bill (SJRES 91) seeks to block a Centers for Medicare & Medicaid Services (CMS) rule that set minimum staffing requirements for long-term care facilities (like nursing homes) and required transparency in Medicaid payments. If passed, it would cancel the rule (89 Fed. Reg. 40876), preventing it from taking effect under a specific congressional review process. The rule directly affects long-term care providers and Medicaid programs by imposing new staffing and reporting requirements. This resolution is procedural - it does not create new law but halts the implementation of the CMS rule.
SRES 722 is a Senate resolution expressing gratitude for the heroism of U.S. Armed Forces members who participated in the D-Day invasion at Normandy, France, on June 6, 1944. It commemorates the 80th anniversary of this pivotal World War II operation, which helped end the war, and commends the leadership and bravery of those who fought. The resolution requests the President issue a proclamation encouraging public ceremonies to honor veterans' sacrifices and recognizes France's efforts to preserve Normandy's historical sites as a UNESCO World Heritage site. As a ceremonial resolution, it has no legal effect but serves to publicly honor historical service and legacy.
SRES 385 is a non-binding Senate resolution calling for the immediate release of Evan Gershkovich, a U.S. citizen and Wall Street Journal journalist wrongfully detained by Russia since March 2023. It urges the U.S. executive branch to press Russia for his release, demands consular access for him, and condemns Russia’s detention of journalists for political purposes. The resolution also specifically calls for the release of Paul Whelan, detained since 2018, and expresses support for other U.S. citizens wrongfully held in Russia. It does not create new legal requirements but formally expresses congressional concern.
The Adoptee Citizenship Act of 2024 grants automatic U.S. citizenship to certain internationally adopted individuals who were adopted by U.S. citizen parents before age 18 and meet specific residency requirements. It directly affects adopted children who were born abroad, never acquired U.S. citizenship before the bill's enactment, and either resided in the U.S. on the bill's effective date (for those already present) or enter the U.S. lawfully (for those abroad). Key provisions include automatic citizenship upon meeting adoption and residency conditions, with exceptions for unresolved criminal activity requiring background checks before visa issuance. The bill does not apply to individuals who already held U.S. citizenship prior to enactment.
The Alzheimer’s Accountability and Investment Act (HR 620) requires the National Institutes of Health (NIH) Director to annually submit a budget estimate for Alzheimer’s-related initiatives - including personnel needs - directly to the President for review and then to Congress. This budget must be prepared after public comment and submitted without changes by the Secretary of Health and Human Services or the Advisory Council. The bill directly affects the NIH’s budget reporting process for Alzheimer’s research and programs, mandating transparency in how funds are allocated. It does not change funding levels but establishes a specific annual reporting mechanism to improve accountability.
This bill reauthorizes the National Alzheimer's Project Act through 2035 (extending the previous deadline of 2025) and adds new requirements to promote healthy aging and reduce Alzheimer’s risk factors. It mandates the program to provide information on healthy behaviors that may lower cognitive decline risk and expands the advisory group to include representatives from agencies like the Department of Justice, FEMA, and Social Security Administration, plus experts with diverse clinical trial experience. The bill directly affects Alzheimer’s research, care programs, and the federal advisory group overseeing national efforts. Key changes include requiring annual evaluations instead of initial ones and adding a focus on reducing health disparities in Alzheimer’s initiatives.
S 4410, the "Stop the ICC Act," bans U.S. government cooperation with the International Criminal Court (ICC) and prohibits federal funding for the ICC itself. It directly affects U.S. foreign aid by blocking Economic Support Funds for the Palestinian Authority if the Palestinians support ICC investigations into Israeli officials, as referenced in the 2024 appropriations law. Key provisions include a blanket prohibition on U.S. officials working with the ICC, cutting aid to the Palestinian Authority tied to ICC involvement, and banning all federal funds for the ICC. The bill cites the ICC's 2021 Palestine investigation and recent arrest warrant applications for Israeli leaders as justification for these funding restrictions.
The GPA Act (S 4425) establishes U.S. sanctions against Georgian officials who obstruct Georgia's path to NATO and EU membership, including those involved in significant corruption or actions undermining Georgia's sovereignty. It requires the U.S. to review and potentially suspend foreign assistance to Georgia if the government continues policies that impede democratic development, such as the controversial "foreign agents bill" that restricts civil society. The legislation includes provisions to support Georgia's democratic institutions, free elections, and civil society while emphasizing U.S. support for Georgia's territorial integrity within internationally recognized borders. It also mandates reports on disinformation, political prisoners, and corruption in Georgia, reflecting U.S. concerns about democratic backsliding and Georgia's relationship with Russia. The act includes a sunset provision, expiring five years after enactment.
The Promising Pathway Act 2.0 creates a new FDA pathway for conditional approval of drugs treating rare, progressive, and serious diseases. This allows patients with limited treatment options to access promising new drugs sooner, based on preliminary safety data from Phase 1 trials and effectiveness data from Phase 2 trials (or preliminary evidence for terminal pediatric rare diseases). The law requires drug sponsors to establish observational registries tracking patient outcomes, mandates specific labeling for conditionally approved drugs, and requires private health insurers and federal health care programs to cover these drugs without cost-sharing. Conditional approval is initially granted for 2 years with potential for up to 3 renewals (totaling 8 years), but can be withdrawn if safety data changes or sponsors fail to meet requirements.
